Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-Ⅲ)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1630 participants.
Also called NCT05745259
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,630 participants
- Sponsor
- Registry
-
NCT05745259
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05745259. Randomized; single masking; primary purpose treatment. Start 2022-10-26 (actual); primary completion 2023-11-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-Ⅲ)
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Alteplase
- Intervention (Drug)
- Tenecteplase
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd
- Collaborator
- The Place Pharmaceutical(Jiangsu) Co., Ltd
Record details
- Record id
cardio:ct-nct05745259- Content hash
7283bd8a2f946669f3e85afc9a5196daf3301a49a3c3d9b5b3d7e71a47014de6